

SCIENTIFIC REPORTS



OPEN

Dual-functionalized liposomal delivery system for solid tumors based on RGD and a pH-responsive antimicrobial peptide

Qianyu Zhang*, Libao Lu*, Li Zhang, Kairong Shi, Xingli Cun, Yuting Yang, Yayuan Liu, Huile Gao & Qin He

Received: 16 June 2015
Accepted: 23 November 2015
Published: 04 February 2016

[D]-H₆L₉, as a pH-responsive anti-microbial peptide (AMP), has been evidenced by us to be an excellent choice in tumor microenvironment-responsive delivery as it could render liposomes responsive to the acidified tumor microenvironment. However, [D]-H₆L₉-modified liposomes could not actively target to tumor area. Therefore, integrin $\alpha_v\beta_3$ -targeted peptide RGD was co-modified with [D]-H₆L₉ onto liposomes [(R + D)-Lip] for improved tumor delivery efficiency. Under pH 6.3, (R + D)-Lip could be taken up by C26 cells and C26 tumor spheroids (integrin $\alpha_v\beta_3$ -positive) with significantly improved efficiency compared with other groups, which was contributed by both RGD and [D]-H₆L₉, while RGD did not increase the cellular uptake performance on MCF-7 cells (integrin $\alpha_v\beta_3$ -negative). Results showed that RGD could decrease cellular uptake of (R + D)-Lip while [D]-H₆L₉ could increase it, implying the role of both RGD and [D]-H₆L₉ in cellular internalization of (R + D)-Lip. On the other hand, (R + D)-Lip could escape the entrapment of lysosomes. PTX-loaded (R + D)-Lip could further increase the cellular toxicity against C26 cells compared with liposomes modified only with RGD and [D]-H₆L₉ respectively, and achieve remarkable tumor inhibition effect on C26 tumor models.

Lowered extracellular pH has been highlighted as one of the major heterogeneity of tumors, which was triggered by the hypoxia and the abnormal tumor metabolic process, leading to the acidification of tumor extracellular environment^{1–3}. This unique feature of tumors could be utilized to design pH-responsive platforms. Among them, histidine-based drug delivery systems have received considerable attention^{4–7}. With a pKa around 6.5, the imidazole ring on histidine confers the ability to donate or receive protons to histidine³, meaning that it could protonate into a positively-charged state under acidic tumor microenvironment yet remain slightly negatively charged in tissues with normal physiological condition. Histidine-rich cell penetrating or membrane-lytic peptides were thus designed^{8–14}, and their indiscriminate and strong penetration in normal tissues could be alleviated; while in acidified environment such as tumors, their membrane-permeation ability and other activity could be restored.

pH-responsive peptides could also be anchored to nano-carriers, bestowing nano-carriers with pH-responsiveness as well^{13–17}. We have already constructed a pH-responsive anti-microbial peptide (AMP) [D]-H₆L₉-mediated PEGylated liposome (D-Lip) in our previous work^{16,17} and it showed competence in tumor cellular delivery both *in vitro* and *in vivo*. Although nano-carriers of this kind could be more efficiently internalized by tumor cells under acidified environment, this was realized only by the passive accumulation of surface-PEGylated nano-carriers (liposomes or polymeric micelles) by EPR effect, since these peptides were not tumor-homing peptides with targeting capacity. Therefore, the introduction of proper ligands that could specifically recognize tumors was necessary.

Besides the acidification by aerobic glycolysis in tumors, angiogenesis was another important hallmark of cancers that were ubiquitous in solid tumors, playing important role in tumor growth and metastasis^{18,19}. Integrin $\alpha_v\beta_3$ are universally expressed in a myriad of tumors, and could be considered as tumor-specific receptors which could be targeted by circulating ligands²⁰, including cyclic RGD²¹. As an excellent tumor-targeting moiety, RGD or RGD-anchored nano-carriers could target tumors with efficiency^{22–24}. It could be combined with other ligands

Key Laboratory of Drug Targeting and Drug Delivery Systems, West China School of Pharmacy, Sichuan University, No. 17, Block 3, Southern Renmin Road, Chengdu 610041, China. *These authors contributed equally to this work. Correspondence and requests for materials should be addressed to Q.H. (email: qinhe@scu.edu.cn)




Figure 1. Schematic illustration of (R + D)-Lip. (A) The structure of (R + D)-Lip and its surface charge variation under different pH. (B) Within tumors, the RGD peptide could recognize integrin $\alpha_v\beta_3$ that was highly expressed on tumor cells, and [D]-H₆L₉ with activated cell penetrating capacity in tumor microenvironment could help deliver (R + D)-Lip intracellularly. This process was contributed by both RGD and [D]-H₆L₉, and (R + D)-Lip could escape the entrapment of endo/lysosomes with the aid of the pH-responsive peptide [D]-H₆L₉.

	Size(nm)	PDI	Zeta potential(mV)
PEG-Lip (pH 7.4)	120.8 ± 5.6	0.198 ± 0.021	-7.8 ± 1.2
R-Lip (pH 7.4)	130.7 ± 6.3	0.199 ± 0.034	-2.5 ± 1.1
D-Lip (pH 7.4)	134.1 ± 7.2	0.221 ± 0.023	-8.7 ± 2.2
(R + D)-Lip (pH 7.4)	133.3 ± 8.8	0.232 ± 0.025	-6.2 ± 2.0
PEG-Lip (pH 6.3)	117.6 ± 7.1	0.188 ± 0.032	-6.3 ± 1.3
R-Lip (pH 6.3)	129.3 ± 8.2	0.231 ± 0.022	-4.2 ± 2.1
D-Lip (pH 6.3)	135.1 ± 10.2	0.219 ± 0.045	9.9 ± 1.3
(R + D)-Lip (pH 6.3)	135.3 ± 9.9	0.235 ± 0.033	8.8 ± 2.1

Table 1. The size and zeta potential measurements of liposomes (n ± 3).

or cell penetrating peptides for augmented tumor-targeted delivery in multi-functional nano-carriers^{25–31}. Together with cell penetrating peptides such as TAT, an enhanced photodynamic therapy of HeLa cells and HeLa tumor-bearing mice could be acquired²⁷. When TAT and RGD were co-modified on silica nanoparticles and used for tumor therapy, murine tumor growth could be successfully repressed²⁸. However, TAT, as a typical cell penetrating peptide and without shielding from a hydrophilic protection layer such as PEG, could interact directly with blood serums which altered its pharmacokinetic profiles, jeopardizing its *in vivo* application.

In this work, we engineered a dual-functional liposome [donated as (R + D)-Lip], which was co-decorated by a pH-responsive anti-microbial peptide [D]-H₆L₉ and a specific ligand RGD for tumor delivery. Before reaching tumors, histidine-rich peptide [D]-H₆L₉ was inactivated in blood circulation and normal tissues (pH 7.4). Upon arrival at tumors, RGD as a targeting ligand could identify tumor cells (C26 cells) that expressed integrin $\alpha_v\beta_3$ receptors in the first place. Then the cell permeation by [D]-H₆L₉ could be potentiated in the acidified tumor environment (pH 6.3), boosting tumor-specific delivery of liposome and its cargo. (Fig. 1)

Results

Preparation and characterization of liposomes. Liposomes were prepared with film dispersion method. As could be seen from Tab 1, the sizes of liposomes were all within the range of 115 nm~140 nm, whether under pH 7.4 or pH 6.3, which was suitable for *in vivo* tumor delivery. TEM image and size distribution of PTX-loaded (R + D)-Lip were also displayed in Fig. S1. The entrapment efficiency of PTX by different liposomes all reached beyond 90%, and the loading capacity was 2.75% (w/w) for (R + D)-Lip. The serum stability of liposomes




Figure 2. Variations in turbidity (A), represented by transmittance) and particle sizes (B) of liposomes in 50% FBS in PBS for 24h under 37 °C. (n = 3, mean \pm SD)

could also be validated (Fig. 2), with transmittance hardly changed over 24h, indicating that no aggregation was formed in serum which was due to the PEGylation of liposomes. The most intriguing phenomenon should be the conversion of zeta potentials of [D]-H₆L₉-anchored liposomes [including D-lip and (R + D)-Lip] from negative to positive when the pH value was lowered from 7.4 (normal tissue environment-mimicking) to 6.3 (tumor microenvironment-mimicking) (Table 1). This was due to the protonation of histidines in peptide [D]-H₆L₉, which has already been evidenced by our previous work^{16,17}. It could be seen that (R + D)-Lip also displayed charge reversal capacity (Table 1), showing that the addition of RGD onto liposome surface did not influence the pH-responsiveness of peptide [D]-H₆L₉.

In vitro cellular uptake assay and cell viability assay. Western Blot assay was performed to quantify the expression level of integrin α_v and integrin β_3 on C26 and MCF-7 cells (Fig. S2). According to the results, C26 was selected as the representative $\alpha_v\beta_3$ integrin receptor-positive tumor cells and MCF-7 was the representative of $\alpha_v\beta_3$ integrin receptor-negative tumor cells³²⁻³⁴. On C26 cells, the cellular uptake of R-Lip was 1.42-fold and 1.45-fold compared to PEG-Lip under pH 7.4 and pH 6.3 respectively, demonstrating the introduction of RGD did facilitate the cellular uptake efficiency of liposomes by $\alpha_v\beta_3$ -positive tumor cells (Fig. 3A). By contrast, this preferential uptake of R-Lip over PEG-Lip did not happen on MCF-7 cells (Fig. 3B). D-Lip showed pH-responsive cellular uptake profile on both C26 cells (3.07-fold increase under pH 6.3 compared to pH 7.4) and MCF-7 cells (4.49-fold increase under pH 6.3 compared to pH 7.4). Similarly, (R + D)-Lip exhibited pH-responsiveness on both cells, although to different degrees: on C26 cells, cellular uptake efficiency increased by 4.25-fold under pH 6.3 compared with pH 7.4, showing that the cellular uptake of (R + D)-Lip by $\alpha_v\beta_3$ -positive tumor cells such as C26 was mediated by both was contributed by both RGD and [D]-H₆L₉. On the contrary, RGD did not increase the cellular uptake of (R + D)-Lip by MCF-7 cells under pH 6.3 compared with D-Lip. As for the cytotoxicity of PTX-loaded liposomes assessed by MTT assay, it could also be concluded that the cytotoxicity of PTX-loaded (R + D)-Lip on C26 cells under pH 6.3 was due to the combination of RGD and [D]-H₆L₉ (Fig. 3C), while on MCF-7 cells, the presence of RGD on the surface of liposomes did not promote cytotoxicity of PTX-loaded liposomes (Fig. 3D). Detailed cellular inhibition rates of different liposomes could be found in Tables S1 and S2.

Effect of free peptide solution on cellular uptake and subcellular localization. The competitive inhibition assay was to discern the impact of excessive free [D]-H₆L₉ or RGD peptide on cellular uptake of (R + D)-Lip. After 2 h, free [D]-H₆L₉ turned to somewhat promote the cellular uptake of (R + D)-Lip, while it was notable that free RGD could strongly suppress the cellular endocytosis process (Fig. 4A).

It was shown in Fig. 4B that within 1 h, CFPE-labeled (R + D)-Lip was mostly adjacent to cellular membrane and distributed within cellular periphery. Liposomes with positive charged surface (both cationic liposomes and cationic CPP-mediated liposomes) were often found within the peripheral part of cells after a short period of cellular uptake^{15,35,36}. After 4 h, C26 cells could readily take up (R + D)-Lip. Although there was some overlap of lysosomes and liposomes (shown in color yellow), the fluorescence of most (R + D)-Lip was found to be outside the lysosomes (Fig. 4B). This should be owing to the presence of [D]-H₆L₉ on the liposomes as we have evidenced in our previous work^{16,17}, that [D]-H₆L₉ containing liposomes could escape or evade the entrapment of lysosomes.

Tumor spheroid uptake assay. Similar to the results of cellular uptake in 3.2, D-Lip and (R + D)-Lip exhibited improved tumor spheroid uptake under pH 6.3 compared with 7.4 (Fig. 5). It was noteworthy that under pH 6.3, (R + D)-Lip seemed to be able to accumulate more into the spheroids compared with other groups. This should be attributed to the combined mediation of [D]-H₆L₉ and RGD.

In vivo and ex vivo biodistribution. Due to PEGylation on liposome surfaces, all four groups of liposomes could reach tumors with efficiency (Fig. 6). As time prolonged from 4 h to 24 h, DiR-labeled liposomes started to accumulate into tumor area (Fig. 6A), and this passive accumulation was mainly due to the EPR effect. Ex vivo fluorescent images of different organs were also captured (Fig. 7B). It showed that the distribution of liposomes in hearts, lungs and kidneys were quite minimal, and their distribution in spleens and livers were quite




Figure 3. Cellular uptake of liposomes by C26 (A) integrin $\alpha_v\beta_3$ -positive cells and MCF-7 (B) integrin $\alpha_v\beta_3$ -negative cells determined by flow cytometry as well as the IC₅₀ values of PTX-loaded liposomes on C26 (C) and MCF-7 (D) tumor cells determined by MTT assay. ** indicated $p < 0.05$ and N.S indicated no significant difference. ($n = 3$, mean \pm SD)

similar to each other. However, liposomes modified with RGD [including R-Lip and (R + D)-Lip] appeared to be able to accumulate more into tumor area compared with the other two groups (PEG-Lip and D-Lip). The observation on the tumor cyro-sections demonstrated that (R + D)-Lip could be taken up more readily than all the other groups, which might result from the promotion of both [D]-H₆L₉ and RGD (Fig. S3).

Therapeutic evaluation. Compared to all the other groups, the dual-functional liposome (R + D)-Lip could result in more significant tumor growth suppression, and the body weights of all groups hardly dropped during the treatment, implying that all the PTX-loaded liposomes showed little *in vivo* toxicity (Fig. 7A,B). High CD133 expression was considered as one of the typical features of stem cells including some cancer stem cells (CSCs). Therefore, we also assessed the CD133 expression level of different tumor by immunohistochemical staining. It was found out that the CD133-positive cells from the sections of the (R + D)-Lip group appeared to be the least among all the groups (Fig. 7C,D).

Discussion

Over decades of development, nano-carriers for tumors have evolved from simple and inert drug vehicles to drug delivery platforms which were tumor-targeted or highly tumor microenvironment-responsive. Therefore, a dual-functionalized liposomal delivery system co-modified by RGD and pH-responsive AMP [D]-H₆L₉ has been devised by us [(R + D)-Lip]. Due to the presence of [D]-H₆L₉, the zeta potential of both D-Lip and (R + D)-Lip could be reversed from negative to positive when pH dropped from 7.4 to 6.3 owing to the protonation of histidine. This in turn led to the significantly improved cellular uptake efficiency on both C26 cells and MCF-7 cells under pH 6.3. However, the introduction of RGD further improved the cellular uptake efficiency of (R + D)-Lip on C26 cells, which was considered as the representative $\alpha_v\beta_3$ integrin receptor-positive tumor cells. The same phenomenon was not observed on MCF-7 cells, on which the expression of $\alpha_v\beta_3$ integrin receptor was negative^{32–34}.

Meanwhile, PTX-loaded (R + D)-Lip could induce the most prominent cellular cytotoxicity under pH 6.3 on C26 cell, implying that the combined effect of both RGD and [D]-H₆L₉ could help deliver more liposomes into $\alpha_v\beta_3$ integrin-positive cells. Multi-functional nano-carriers could draw on the advantages of different targeting ligands, achieving a much more efficient targeted delivery than liposomes with single ligands in synergistic or combined manner^{37–40}. Among them, nano-carriers modified with one specific ligand and one cell penetrating peptides have attracted considerable attention^{25,39,40}. Specific ligand-mediated intracellular delivery was often not efficient enough owing to the fact that receptor-dependent pathway mediated by specific ligand was




Figure 4. (A) CLSM images of C26 cells that have been incubated with CFPE-labeled (R + D)-Lip in the presence of free RGD peptide or [D]-H₆L₉. (B) Lysosome staining after C26 cells were treated with CFPE-labeled (R + D)-Lip for 1 or 4 h. Scale bar represents 20 μm.

often saturated²⁵, therefore the addition of CPPs could greatly improve cellular delivery. [D]-H₆L₉, as a cellular membrane-permeable peptide, acted as the role of a pH-responsive cell penetrating peptide in our work.

It has been reported that $\alpha_v\beta_3$ integrin receptor-dependent endocytosis was ligand-specific and saturable^{25,31}, therefore excessive RGD peptide could block the $\alpha_v\beta_3$ receptor beforehand, resulting in decreased internalization of (R + D)-Lip. As for free [D]-H₆L₉, although apparently there was no specific receptor for it on C26 cells, as an AMP which could disrupt membrane integrity in the membrane-depolarizing lytic mechanism, could possibly destabilize and permeate cellular membrane when applied under higher concentration⁹, thus facilitating the intracellular transport of (R + D)-Lip.

Receptor-dependent (in our case, $\alpha_v\beta_3$ integrin receptor-dependent) endocytosis was often related with endo/lysosomes^{41,42}, however, our results proved that (R + D)-Lip hold the potential to escape the confinement of lysosomes. This was contributed by peptide [D]-H₆L₉, which could cause strong membrane destabilization under endo/lysosome environment, releasing liposomes from endo/lysosomes, which was beneficial for intracellular drug delivery as we have proved before¹⁶.

Tumor spheroids were favorable and simple models for tumor chemotherapy evaluation⁴³. It could in a way predict the diffusion-based transport of nanoparticles in a milieu that better reflects the structural and microenvironmental heterogeneity commonly associated with solid tumors⁴⁴. RGD was known for its solid tumor penetration capacity which was mediated by integrin-dependent transcytosis into deeper tumor issues^{45,46}. Together with [D]-H₆L₉, (R + D)-Lip appeared to be able to permeate into the inner area of tumor spheroids. It has been reported that hypoxia areas and pH gradients exists within tumor spheroids and the core could be further acidified thereafter⁴⁷. Therefore theoretically, it was possible that [D]-H₆L₉ could be activated in the core with lowered pH and (R + D)-Lip was able to penetrate into and stay in tumor cells within the deeper area in tumor spheroids compared to other groups. In this work, R-Lip did not seem to exhibit significant penetration on spheroids, probably because the uptake of CFPE-labeled liposomes by spheroids remained on a lower level compared to D-Lip and (R + D)-Lip (under pH 6.3) and the penetration capacity was not as excellent as (R + D)-Lip in an *in vitro* model. The biodistribution of different liposomes and their *in vivo* property should be further investigated.

As indicated by our previous work, [D]-H₆L₉ did not possess active tumor-homing capacity^{16,17}. Meanwhile, it has been confirmed that RGD could be considered as tumor-homing ligand and applied in active targeting of various tumors for altered and enhanced tumor accumulation^{48–50}. *In vivo*, RGD could bind with tumor blood vessel or even tumor cells that overexpressed $\alpha_v\beta_3$ integrin receptor to realize active tumor targeting^{25,51}. It has been




Figure 5. CLSM images showing the uptake of CFPE-labeled liposomes on C26 tumor spheroids after 2 h. Scale bar represented 150 μm .

reported that vascular targeting by RGD-functionalized nano-carriers was feasible, which resulted in rapid and efficient early binding to tumor blood vessels. Overtime, passive targeting (EPR effect) stepped in and was more efficient by solely vascular targeting, and in return led to higher overall tumor retention levels⁵². This accounted for the increased accumulation of R-Lip and (R + D)-Lip in tumors. This meant that (R + D)-Lip that we have constructed in this work owned distinct advantages over the D-Lip we have previously constructed.

CD133 expression was a very typical feature of stem cells, and has been identified as a special marker for cancer stem cells (CSCs)⁵³. CSCs were considered to be resistant to chemotherapy, and some studies suggested that CSCs were held as the culprit of tumor metastasis and relapse⁵⁴. Therefore, successful reduction and even eradication of cancer tumor cells would be of potential significance to tumor therapy. Results from Fig. 7C showed that the amount of CD133-positive CSCs from group (R + D)-Lip was minimal among all. It could be concluded from Fig. 5 that (R + D)-Lip could penetrate deeper into the tumor spheroids, and more (R + D)-Lip could be taken up and retained by tumor spheroids than other groups. Combining the results together, we might make a bold speculation that due to the fact that more PTX-loaded (R + D)-Lip could be delivered into tumors, the tumor treatment outcome for PTX-loaded (R + D)-Lip was much better than other groups, which indicated certain significance to tumor therapy. Therefore, (R + D)-Lip proved itself as an outstanding dual-functionalized drug delivery platform for tumor delivery, especially for $\alpha_v\beta_3$ integrin-positive tumor cells with significantly improved tumor therapy effect.

Methods

Materials. SPC (soybean lecithin) was purchased from Shanghai Taiwei Chemical Company (Shanghai, China). Cholesterol was purchased from Kelong Chemical Company (Chengdu, China). DSPE-PEG₂₀₀₀, and 2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(carboxyfluorescein) (CFPE) were purchased from Avanti Polar Lipids (Alabaster, AL, USA). DSPE-PEG₂₀₀₀-Mal was purchased from Shanghai Advanced Vehicle Technology (AVT) L.T.D. Company (Shanghai, China). cRGDfK-cysteine peptide (cycle RGDfK-Cys) and [D]-H₆L₉ peptide with a terminal cysteine (LHLLHLLHLLHLL-Cys, the underlined letters were D-amino acids) were synthesized according to the standard solid phase peptide synthesis by ChinaPeptides Co. Ltd. (Shanghai, China). 1, 10-Dioctadecyl-3, 3', 30, 30'-tetramethylindotricarbocyanine iodide (DiR) was purchased from Biotium. LysoTracker™ was obtained from Invitrogen (Carlsbad, CA, USA). 6-diamidino-2-phenylindole (DAPI) and was purchased from Beyotime Institute Biotechnology (Haimen, China). Other chemicals and




Figure 6. (A) *In vivo* images of C26 tumor-bearing Balb/C mice 4 or 24 h after injection of DiR-labeled liposomes. (B) Ex vivo images of organs or tumor tissues from C26 tumor-bearing Balb/C mice 24 after injection of DiR-labeled liposomes.

reagents were of analytical grade. DSPE-PEG₂₀₀₀-RGD and DSPE-PEG₂₀₀₀-[D]-H₆L₉ were synthesized and purified according to our previously reported methods^{16,31}.

C26 cells (murine colon cancer cells) and MCF-7 cells () were cultured in RPMI-1640 medium (GIBCO) supplemented with 10% FBS at 37 °C in a humidified 5% CO₂ atmosphere. Plastic cell culture dishes and plates were purchased from Wuxi NEST biotechnology Co. (Wuxi, China). BALB/C mice purchased from experiment animal center of Sichuan University (P.R. China). All animal experiments were performed in accordance with the principles of care and use of laboratory animals and were approved by the experiment animal administrative committee of Sichuan University. 6-week to 8-week old Balb/C mice were inoculated with 5×10^5 cells




Figure 7. (A) Tumor growth curves of mice receiving different PTX-loaded liposomes ($n = 6$, mean \pm SD). Black arrows indicate times of administration. (B) Body weight variations of different groups ($n = 6$, mean \pm SD). Black arrows indicate times of administration. (C) Representative CD133 immuno-staining (dark brown) of tumor sections. (D) Quantification of CD133-positive cells in tumor sections from each group. ($n = 6$, mean \pm SD). Images were processed by ImageJ 1.47V. ** indicated $p < 0.05$.

subcutaneously into the left flank. Tumors were allowed to grow to an average volume of 50–100 mm³ (tumor volume = length \times width² \times 0.52) for the biodistribution study.

Preparation and characterization of liposomes. For the preparation of [D]-H₆L₉-anchored liposomes (D-Lip), SPC, cholesterol, DSPE-PEG₂₀₀₀ and DSPE-PEG₂₀₀₀-[D]-H₆L₉ with a molar ratio of 55: 33: 6: 6 were dissolved in the mixture of chloroform and methanol. RGD-anchored liposomes (R-Lip) were prepared with the above materials with DSPE-PEG₂₀₀₀-[D]-H₆L₉ replaced with DSPE-PEG₂₀₀₀-RGD at a molar ratio of 55: 33: 6: 6. [D]-H₆L₉ and RGD co-modified liposomes [denoted as (D + R)-Lip] were prepared with SPC, cholesterol, DSPE-PEG₂₀₀₀-[D]-H₆L₉ and DSPE-PEG₂₀₀₀-RGD with a molar ratio of 55: 33: 6: 6. The PEGylated liposomes (PEG-Lip) were prepared with SPC, cholesterol and DSPE-PEG₂₀₀₀ at a molar ratio of 57: 33: 10. The organic solvents were removed by rotary evaporation, and a thin lipid film was formed and further dried under vacuum overnight for the removal of remaining solvents. The lipid film was hydrated with appropriate volume of 5% glucose solution and incubated under 37 °C with shaking for 30 min. The obtained liposomes were further dispersed by being intermittently sonicated by a probe sonicator. CFPE, DiR and paclitaxel (PTX) were added to the lipid solution respectively to form the fluorescently labeled or drug-loaded liposomes. Mean particle sizes and zeta potentials of liposomes were measured by Malvern Zetasizer Nano ZS90 instrument (Malvern Instruments Ltd., U.K.). The entrapment efficiency (EE%) of PTX was determined by HPLC.

In order to characterize the serum stability of liposomes, variations in turbidity of liposomes in serum were monitored (Thermo Scientific Varioskan Flash, USA). 100 μ L liposomes were mixed with 100 μ L fetal bovine serum (FBS) under 37 °C with mild oscillation, and the turbidity was read at each predetermined time points.

In vitro cellular uptake assay. C26 cells were planted at a density of 1×10^5 cells/well into 6-well plates and allowed to grow for 24 h. CFPE-labeled liposomes were applied in fresh cell culture medium, and liposome-free culture medium was considered as the control. Two hours after incubation under 37 °C, cells were washed with cold PBS for three times and then trypsinized and resuspended in 0.4 mL PBS. The fluorescent intensity of cells was measured by a flow cytometer (Cytomics™ FC 500, Beckman Coulter, Miami, FL, USA) with the excitation wavelength at 495 nm and the emission wavelength at 515 nm. Ten thousand events were recorded for each sample.

Cell viability assay. 5×10^3 C26 cells were seeded into each well of a 96-well plate. After attachment, cell culture medium was evacuated and liposome-containing medium was added to each well. Twenty four hours

later, cytotoxicity was evaluated with MTT assay, with the absorbance read at 570 nm. Non-treated cells were used as controls. All the measurements were repeated in triplicates.

Effect of free peptide solutions on cellular uptake. C26 cells were seeded onto gelatin-coated cover slip at a density of 2×10^4 cells/well in a 6-well plate. Twenty-four hours later, cells were treated with free [D]-H₆L₉ peptide or RGD peptide-containing cell culture medium for 1 h. Then CFPE-labeled (R + D)-Lip were added to cell culture medium and the incubation continued for another 2 h under 37 °C. The cells were washed and fixed with 4% paraformaldehyde and nuclei were stained with DAPI for 5 min followed by washing with cold PBS for 3 times. Coverslips were mounted cell-side down and viewed by confocal microscopy (FV1000, Olympus, USA).

Subcellular localization. For subcellular localization study, C26 cells were seeded onto gelatin-coated cover slip at a density of 2×10^4 cells/well. After 24 h, cells were applied with CFPE-labeled (R + D)-Lip in cell culture medium and incubated for 0.5 h or 4 h. By the end of incubation, lysotracker red (50 nM) was added into each well and incubated for 30 min. Cells were then washed rapidly with ice cold PBS and fixed with 4% paraformaldehyde at room temperature for 15 min and the nuclei were stained with DAPI for 5 min, and the cells were for visualization (FV1000, Olympus, USA).

Tumor spheroid uptake assay. C26 cells were trypsinized and resuspended in 1640 cell culture medium at a density of 2×10^3 cells/100 μ L, and were added to 2% agarose-coated 96-well plate. The formation of C26 tumor spheroids was monitored by optical microscope. Then the spheroids were incubated with CFPE-labeled liposomes for 2 h, gently washed with cold PBS by pipetting, and were fixed in 4% paraformaldehyde under room temperature. Fluorescent images were taken under confocal microscope (FV1000, Olympus, USA).

In vivo and ex vivo biodistribution. C26 tumor-bearing Balb/C mice were randomly divided into different groups with 3 mice each. For the *in vivo* and *ex vivo* imaging, DiR-loaded liposomes were intravenously injected at a dose of 200 μ g DiR/kg. Twenty four hours after injection, mice were imaged with with IVI[®] Spectrum system (Caliper, Hopkington, MA, USA). Then the mice the executed with cervical dislocation and vital organs and tissues (including hearts, livers, spleens, lungs, kidneys and tumors) were taken out and also imaged. For the cyro-section observation, mice were injected with DiD-labeled liposomes. Twenty four hours later, mice were sacrificed with heart perfusion of saline. Tumors were harvested and cyro-sectioned at a thickness of 10 μ m, and sections were treated with 4% paraformaldehyde and DAPI, and were imaged under confocal microscope.

Therapeutic evaluation. Treatment started on the 5th day of tumor inoculation, and mice were assigned into 6 groups (n = 6) and administered with the following six preparations respectively: PBS, PTX solution (Taxol), PEG-Lip/PTX, D-Lip/PTX, R-Lip/PTX and (D + R)-Lip/ PTX. All the preparations were injected through tail veins every 3 days for 6 times, and tumor volumes were monitored. PTX was administered at a dose of 2 mg/kg. Tumors were dissected afterwards, and immersed in 4% paraformaldehyde. Then tumors were cut into sections of 5 μ m, and treated by CD133 antibody to detect the expression levels of the stem cell marker CD133.

References

- Vaupel, P., Kallinowski, F. & Okunieff, P. Bloodflow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. *Cancer Res.* **49**, 6449–6465 (1989).
- Svastová, E. *et al.* Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH. *FEBS Lett.* **577**, 439–445 (2004).
- Tian, L. & Bae, Y. H. Cancer nanomedicines targeting tumor extracellular pH. *Colloids Surf. B Biointerfaces.* **99**, 116–26 (2012).
- Lee, E. S., Na, K. & Bae, Y. H. Super pH-sensitive multifunctional polymeric micelle. *Nano Lett.* **5**, 325–329 (2005).
- Toriyabe, N., Hayashi, Y. & Harashima, H. The transfection activity of R8-modified nanoparticles and siRNA condensation using pH sensitive stearylated-octahistidine. *Biomaterials* **34**, 1337–1343 (2013).
- Wu, H., Zhu, L. & Torchilin, V. P. pH-sensitive poly(histidine)-PEG-DSPE-PEG copolymer micelles for cytosolic drug delivery. *Biomaterials* **34**, 1213–1222 (2013).
- Hu, J., Miura, S., Na, K. & Bae, Y. H. pH-responsive and charge shielded cationic micelle of poly(l-histidine)- block-short branched PEI for acidic cancer treatment. *J Control. Release* **172**, 69–76 (2013).
- Tu, Z., Volk, M., Shah, K., Clerkin, K. & Liang, J. F. Constructing bioactive peptides with pH-dependent activities. *Peptides* **30**, 1523–1528 (2009).
- Makovitzki, A., Fink, A. & Shai, Y. Suppression of human solid tumor growth in mice by intratumor and systemic inoculation of histidine-rich and pH-dependent host defense-like lytic peptides. *Cancer Res.* **69**, 3458–3463 (2009).
- Midoux, P., Kichler, A., Boutin, V., Maurizot, J. C. & Monsigny, M. Membrane permeabilization and efficient gene transfer by a peptide containing several histidines. *Bioconjug. Chem.* **9**, 260–267 (1998).
- Li, L. *et al.* Design and characterization of an acid-activated antimicrobial peptide. *Chem. Biol. Drug Des.* **75**, 127–132 (2010).
- Zhang, W. *et al.* Design of acid-activated cell penetrating peptide for delivery of active molecules into cancer cells. *Bioconjug. Chem.* **22**, 1410–1415 (2011).
- Zhao, B. X. *et al.* The efficiency of tumor-specific pH-responsive peptide-modified polymeric micelles containing paclitaxel. *Biomaterials* **33**, 2508–2520 (2012).
- Jiang, T. *et al.* Dual-functional liposomes based on pH-responsive cell-penetrating peptide and hyaluronic acid for tumor-targeted anticancer drug delivery. *Biomaterials* **33**, 9246–9258 (2012).
- Zhang, Q. *et al.* A pH-responsive α -helical cell penetrating peptide-mediated liposomal delivery system. *Biomaterials* **34**, 7980–7993 (2013).
- Zhang, Q. *et al.* Simultaneous delivery of therapeutic antagonists with paclitaxel for the management of metastatic tumors by a pH-responsive anti-microbial peptide-mediated liposomal delivery system. *J Control. Release* **197**, 208–218 (2015).
- Zhang, Q. *et al.* Development of an anti-microbial peptide-mediated liposomal delivery system: a novel approach towards pH-responsive anti-microbial peptides. *Drug Deliv.* **19**, 1–8 (2015).
- Weis, S. M. & Cheresch, D. A. Tumor angiogenesis: molecular pathways and therapeutic targets. *Nat. Med.* **17**, 1359–1370 (2011).
- Folkman, J. Role of angiogenesis in tumor growth and metastasis. *Semin. Oncol.* **29**, 15–18 (2002).

20. Pasqualini, R., Koivunen, E. & Ruoslahti, E. αv integrins as receptors for tumor targeting by circulating ligands. *Nat. Biotechnol.* **15**, 542–546 (2007).
21. Dechantsreiter, M. A. *et al.* N-Methylated cyclic RGD peptides as highly active and selective $\alpha v \beta 3$ integrin antagonists. *J Med. Chem.* **42**, 3033–3040 (1999).
22. Arap, W., Pasqualini, R. & Ruoslahti, E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. *Science* **1279**, 377–380 (1998).
23. Chen, X., Plasencia, C., Hou, Y. & Neamati, N. Synthesis and biological evaluation of dimeric RGD peptide-paclitaxel conjugate as a model for integrin-targeted drug delivery. *J Med. Chem.* **48**, 1098–1106 (2005).
24. Murphy, E. A. *et al.*, Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis. *Proc. Natl. Acad. Sci. USA* **105**, 9343–9348 (2008).
25. Kibria, G. *et al.* Dual-ligand modification of PEGylated liposomes shows better cell selectivity and efficient gene delivery. *J Control. Release* **153**, 141–148 (2011).
26. Hatakeyama, H., Akita, H. & Harashima, H. A multifunctional envelope type nano device (MEND) for gene delivery to tumours based on the EPR effect: a strategy for overcoming the PEG dilemma. *Adv. Drug Deliv. Rev.* **63**, 152–160 (2011).
27. Pan, L. *et al.* Intranuclear Photosensitizer Delivery and Photosensitization for Enhanced Photodynamic Therapy with Ultralow Irradiance. *Adv. Funct. Mater.* **24**, 7318–7327 (2014).
28. Pan, L., Liu, J., He, Q. & Shi, J. MSN-Mediated Sequential Vascular-to-Cell Nuclear-Targeted Drug Delivery for Efficient Tumor Regression. *Adv. Mater.* **26**, 6742–6748 (2014).
29. Kluzza, E., van der Schaft, D. W. & Hautvast, P. A. Synergistic targeting of $\alpha v \beta 3$ integrin and galectin-1 with heteromultivalent paramagnetic liposomes for combined MR imaging and treatment of angiogenesis. *Nano Lett.* **10**, 52–58 (2010).
30. Meng, S. *et al.* Enhanced antitumor effect of novel dual-targeted paclitaxel liposomes. *Nanotechnology* **21**, 415103 (2010).
31. Mei, L. *et al.* Increased tumor targeted delivery using a multistage liposome system functionalized with RGD, TAT and cleavable PEG. *Int. J Pharm.* **468**, 26–38 (2014).
32. Temming, K. *et al.* Improved Efficacy of $\alpha v \beta 3$ -Targeted Albumin Conjugates by Conjugation of a Novel Auristatin Derivative. *Mol. Pharm.* **4**, 686–694 (2007).
33. Ou, Z. *et al.* Functional single-walled carbon nanotubes based on an integrin $\alpha v \beta 3$ monoclonal antibody for highly efficient cancer cell targeting. *Nanotechnology* **20**, 105102 (2009).
34. Wallbrunn, A. V., Hölzke, C. & Zühlendorf, M. *In vivo* imaging of integrin $\alpha v \beta 3$ expression using fluorescence-mediated tomography. *Eur. J Nucl. Med. Mol. Imaging* **34**, 745–754 (2007).
35. Chernenko, T. *et al.* Raman microscopy for noninvasive imaging of pharmaceutical nanocarriers: intracellular distribution of cationic liposomes of different composition. *Mol. Pharm.* **9**, 930–936 (2012).
36. Liu, Y. *et al.* Paclitaxel loaded liposomes decorated with a multifunctional tandem peptide for glioma targeting. *Biomaterials* **35**, 4835–4847 (2014).
37. Yang, Y. *et al.* Dual-modified liposomes with a two-photon-sensitive cell penetrating peptide and NGR ligand for siRNA targeting delivery. *Biomaterials* **48**, 84–96 (2015).
38. Yu, B. *et al.* Targeted drug delivery and cross-linking induced apoptosis with anti-CD37 based dual-ligand immunoliposomes in B chronic lymphocytic leukemia cells. *Biomaterials* **34**, 6185–6193 (2013).
39. Zong, T. *et al.* Synergistic dual-ligand doxorubicin liposomes improve targeting and therapeutic efficacy of brain glioma in animals. *Mol. Pharm.* **11**, 2346–2357 (2014).
40. Takara, K. *et al.* Size-controlled, dual-ligand modified liposomes that target the tumor vasculature show promise for use in drug-resistant cancer therapy. *J Control. Release* **162**, 225–232 (2012).
41. Nam, H. Y. *et al.* Cellular uptake mechanism and intracellular fate of hydrophobically modified glycol chitosan nanoparticles. *J Control. Release* **135**, 259–267 (2009).
42. Xiang, S. *et al.* Uptake mechanisms of non-viral gene delivery. *J Control. Release* **158**, 371–378 (2012).
43. Perche, F., Patel, N. R. & Torchilin, V. P. Accumulation and toxicity of antibody-targeted doxorubicin-loaded PEG-PE micelles in ovarian cancer cell spheroid model. *J Control. Release* **164**, 95–102 (2012).
44. Mikhail, A. S. *et al.* Image-based analysis of the size- and time-dependent penetration of polymeric micelles in multicellular tumor spheroids and tumor xenografts. *Int. J Pharm.* **464**, 168–177 (2014).
45. Waite, C. L. & Roth, C. M. Binding and transport of PAMAM-RGD in a tumor spheroid model: The effect of RGD targeting ligand density. *Biotechnol Bioeng* **108**, 2999–3008 (2011).
46. Jiang, X. *et al.* Solid tumor penetration by integrin-mediated pegylated poly(trimethylene carbonate) nanoparticles loaded with paclitaxel. *Biomaterials* **34**, 1739–1746 (2013).
47. Mehta, G. *et al.* Opportunities and challenges for use of tumor spheroids as models to test drug delivery and efficacy. *J Control. Release* **164**, 192–204 (2012).
48. Lee, H. Y. *et al.* PET/MRI Dual-Modality Tumor Imaging Using Arginine-Glycine-Aspartic (RGD)-Conjugated Radiolabeled Iron Oxide Nanoparticles. *J Nucl. Med.* **49**, 1371–1379 (2008).
49. Xiong, X. B. *et al.* Enhanced intracellular delivery and improved antitumor efficacy of doxorubicin by sterically stabilized liposomes modified with a synthetic RGD mimetic. *J Control. Release* **107**, 262–275 (2005).
50. Verbeek, F. P. *et al.* Near-Infrared Fluorescence Imaging of Both Colorectal Cancer and Ureters Using a Low-Dose Integrin Targeted Probe. *Ann. Surg. Oncol.* **21** Suppl 4, S528–S537 (2014).
51. Sugahara, K. N. *et al.* Tissue-Penetrating Delivery of Compounds and Nanoparticles into Tumors. *Cancer Cell* **16**, 510–520 (2009).
52. Kunjachan, S. *et al.* Passive versus Active Tumor Targeting Using RGD- and NGR-Modified Polymeric Nanomedicines. *Nano Lett.* **14**, 972–981 (2014).
53. Collins, A. T. *et al.* Prospective identification of tumorigenic prostate cancer stem cells. *Cancer Res.* **65**, 10946–10951 (2005).
54. Clevers, H. The cancer stem cell: premises, promises and challenges. *Nat. Med.* **17**, 313–319 (2011).

Acknowledgements

The work was funded by the National Basic Research Program of China (973 Program, 2013CB932504), the National Natural Science Foundation of China (81373337), and Sichuan Province Infrastructure Platform of Science and Technology (15010116).

Author Contributions

Q.Z., L.L. and Q.H. conceived the project, conducted the experiment and wrote the paper. L.Z., K.S., X.C., Y.Y., Y.L. and H.G. provided assistance in experiment performing.

Additional Information

Supplementary information accompanies this paper at <http://www.nature.com/srep>

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Zhang, Q. *et al.* Dual-functionalized liposomal delivery system for solid tumors based on RGD and a pH-responsive antimicrobial peptide. *Sci. Rep.* **6**, 19800; doi: 10.1038/srep19800 (2016).



This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>